Shipments of COVID-19 Diagnostic Tests Top 1 Million Daily
Last week shipments of COVID-19 molecular tests reached an all-time high of 1 million, according to AdvaMed’s Diagnostic Supply Registry. As of July 28, FDA authorized 158 molecular tests under EUAs, and nearly 80 million have been manufactured and shipped since March. Molecular test production also increased from nearly 450,000 daily shipments in May to 870,000 daily shipments by July 18.
According to the national registry, about 95% of the COVID-19 tests currently on the market in the United States are manufactured by 13 diagnostic companies:
- Abbott
- Beckman Coulter
- Hologic
- Roche
- Bio-Rad
- BioMérieux
- Ortho Clinical Diagnostics
- Thermo Fisher Scientific
- Sekisui
- Becton Dickinson
- Cepheid
- Siemens Healthineers
- Qiagen
Related Articles
-
The omicron variant of the coronavirus has made clear that the impact of the pandemic is far from over, particularly for health systems and hospitals. The ongoing need to limit close contact between providers and patients means technology will continue…
-
The acquisition expands MilliporeSigma’s portfolio to a full range of bioreactors, from 2ml to 2000L, and adds to the company’s expertise in monoclonal antibody (mAb) process development.
-
Bringing design and quality assurance processes together earlier in the device development process can reduce costs and nonconformances, while improving outcomes.
-
The acquisition brings MAXIS’ expertise in pre-clinical engineering, design validation and verification, regulatory affairs, field clinical services, and trial management to Avania’s contract research and MedTech development capabilities.
